April 27, 2015

VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer

September 3, 2014

Ludwig Cancer Research and Cancer Research Institute Collaborate on Evaluation of VentiRx's Investigational Immunotherapy

September 2, 2014

VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer

September 2, 2014

VentiRx Pharmaceuticals Provides Corporate and Clinical Update - Management Team, Funding, Immunotherapy Trials

April 17, 2014

VentiRx Pharmaceuticals Announces the Completion of Patient Enrollment in Randomized, Placebo-controlled Phase 2 Trial of VTX-2337 in Combination with Pegylated-Liposomal Doxorubicin in Platinum-resistant Ovarian Cancer

February 20, 2014

VentiRx Pharmaceuticals Presents Phase 1 Data on VTX-2337 at 2014 Multidisciplinary Head and Neck Cancer Symposia

July 2, 2013

VentiRx Pharmaceuticals Initiates the ACTIVE8 Phase 2 Clinical Trial Evaluating VTX-2337 in Combination with Cetuximab and Chemotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

June 3, 2013

Preclinical and Phase 1 Data of VTX-2337 Presented at 2013 ASCO Annual Meeting Shows Early Activity in Ovarian Cancer

April 22, 2013

VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer

October 22, 2012

VentiRx Pharmaceuticals Initiates Randomized, Placebo-Controlled, Phase 2 Trial of VTX-2337 in Patients with Recurrent or Persistent Ovarian Cancer

October 3, 2012

VentiRx Pharmaceuticals Announces Exclusive, Strategic Collaboration for Development of Novel TLR8 Agonist VTX-2337 with Celgene Corporation

January 23, 2012

VentiRx Pharmaceuticals Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting its Potential as an Immunotherapeutic Approach in Cancer

June 6, 2011

VentiRx Pharmaceuticals Presents Results from Phase 1 Clinical Trial of VTX-2337, a Novel TLR8 Agonist, in Patients with Advanced Solid Tumors at American Society of Clinical Oncology Annual Meeting

March 21, 2011

VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy & Immunology Annual Meeting

October 7, 2010

VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis - Establishes Proof of Concept for First In Class TLR8 Agonist in Allergy

October 4, 2010

VentiRx Pharmaceuticals' Novel TLR8 Agonist, VTX-2337, Successfully Completes Phase 1 Clinical Trial in Oncology

September 15, 2010

FierceBiotech Names VentiRx Pharmaceuticals as One of the 'Fierce 15' Biotech Companies of 2010 - VentiRx is on the Leading Edge of Biotech

January 12, 2010

VentiRx Pharmaceuticals Raises $25 Million in Series A Extension Financing - Funds used for clinical development of the first selective TLR8 agonists

April 16, 2009

VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis - First Selective TLR8 Agonist to Advance for Treatment of Allergy

December 4, 2008

VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology - First Selective TLR8 Agonist to Advance to Clinical Trials

May 23, 2008

VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors

April 16, 2007

VentiRx Pharmaceuticals Appoints Kent Snyder to Board of Directors

March 13, 2007

Array BioPharma and VentiRx Pharmaceuticals Announce License Agreement

March 6, 2007

VentiRx Pharmaceuticals Announces $28.9 Million Financing